Dems Pressure Treasury Over Retroactive R&E Expensing Loophole
A group of nine Democratic lawmakers is challenging Treasury to reject creating a Corporate Alternative Minimum Tax (CAMT) carveout for firms that accelerate their research and experimental (R&E) expense deductions under the transition rules of the One Big Beautiful Bill Act (OBBB). Led by Senator Elizabeth Warren (D-MA), the December 3 letter (link provided in the original) asks for a detailed assessment of how such a carveout would affect the national debt.
R&E Expensing and CAMT: The Interaction
The OBBB reinstated full, immediate domestic R&E expensing, undoing a prior rule that from January 1, 2022 required five-year amortization. The act also included transition provisions for taxpayers already mid-amortization.
For domestic R&E expenses paid or incurred in tax years 2022 through 2024 that were previously amortized over five years, taxpayers have two options: either deduct any remaining unamortized amount in the first year after December 31, 2024, or spread the remaining amount evenly over the next two years.
Trade groups such as the National Foreign Trade Council (NFTC) and the R&D Coalition warn that the interaction between the OBBB’s R&E expensing provisions and CAMT could produce unintended outcomes.
CAMT, typically a 15% minimum tax on the adjusted financial statement income (AFSI) of large corporations, ensures that firms with substantial book income pay at least a minimum tax even if their taxable income is reduced by deductions or credits.
According to NFTC’s September 30 letter to Treasury (reference in the original), reinstating full R&E expensing in 2025 alongside prior-year amortization could create a disconnect: a reduction in taxable income and ordinary tax liability without a corresponding decrease in AFSI. NFTC recommends allowing taxpayers to adjust their AFSI for CAMT purposes to reflect domestic R&D expenditures paid or incurred in taxable years after December 31, 2021 and before January 1, 2025.
Andrew Lautz of the Bipartisan Policy Center explained the CAMT–R&E expensing interplay in an October explainer. He warned that 2025 could pose a particular challenge for companies because accelerated deductions from 2022–2024 stacking on top of full R&E expensing in 2025 may push taxable income well below book income.
Dems Push Back on a Carveout
Warren and her colleagues argue that creating a carveout as the NFTC proposes would undermine CAMT’s purpose: to ensure that no billionaire-backed corporation pays less than 15% on the income it reports to shareholders. Excluding retroactive R&E expensing from AFSI would amount to a large, new tax loophole, they contend.
The December 3 letter emphasizes the prospective availability of retroactive R&E expensing under the new law—potentially allowing companies to accelerate about $67 billion in deductions in 2026 alone. By reducing tax liability, such accelerated deductions would be limited by CAMT, the lawmakers say, making CAMT the essential guardrail.
Lautz notes that the shift to immediate full R&E expensing, despite the complications, had bipartisan backing, and the transition was inherently bumpy. He suggests that either party could have anticipated the book-to-tax issues raised by accelerating R&D deductions.
Another concern is that retroactive expensing does not directly spur new R&D activity because it affects deductions for investments already made. Warren has previously warned that retroactive cuts are likely to provide a one-time cash windfall that corporations could use for higher executive compensation or shareholder returns rather than funding fresh R&D.
Lautz counters that while retroactive expensing doesn’t directly incentivize new R&D, it can indirectly support it by freeing up capital.
In a subsequent request, Warren and her colleagues asked Treasury Assistant Secretary for Tax Policy Ken Kies and Treasury Secretary Scott Bessent to respond by December 17 with information on regulatory changes under consideration to address R&E expensing and CAMT interactions. They also requested data on how many companies would see reduced tax liability if retroactive R&E expenses could be subtracted from AFSI, and what that would mean for the national debt.
Would you like deeper explanations of how CAMT interacts with R&E policies in practice, or a side-by-side comparison of the potential tax outcomes under different scenarios?
